

Peter Dorfmler

List of Publications by Citations

Source: <https://exaly.com/author-pdf/8377857/peter-dorfmueller-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

58
papers

4,678
citations

33
h-index

61
g-index

61
ext. papers

5,911
ext. citations

10.3
avg, IF

5.05
L-index

#	Paper	IF	Citations
58	Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives. <i>European Respiratory Journal</i> , 2019 , 53,	13.6	407
57	Relevant issues in the pathology and pathobiology of pulmonary hypertension. <i>Journal of the American College of Cardiology</i> , 2013 , 62, D4-12	15.1	379
56	Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008 , 178, 81-8	10.2	336
55	Endothelial-to-mesenchymal transition in pulmonary hypertension. <i>Circulation</i> , 2015 , 131, 1006-18	16.7	320
54	EIF2AK4 mutations cause pulmonary veno-occlusive disease, a recessive form of pulmonary hypertension. <i>Nature Genetics</i> , 2014 , 46, 65-9	36.3	259
53	Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases. <i>Human Pathology</i> , 2007 , 38, 893-902	3.7	238
52	Pulmonary veno-occlusive disease: clinical, functional, radiologic, and hemodynamic characteristics and outcome of 24 cases confirmed by histology. <i>Medicine (United States)</i> , 2008 , 87, 220-233	1.8	229
51	Pulmonary lymphoid neogenesis in idiopathic pulmonary arterial hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012 , 185, 311-21	10.2	194
50	Pulmonary arterial hypertension. <i>Orphanet Journal of Rare Diseases</i> , 2013 , 8, 97	4.2	168
49	Microvascular disease in chronic thromboembolic pulmonary hypertension: a role for pulmonary veins and systemic vasculature. <i>European Respiratory Journal</i> , 2014 , 44, 1275-88	13.6	135
48	Pulmonary veno-occlusive disease. <i>European Respiratory Journal</i> , 2016 , 47, 1518-34	13.6	134
47	Increased pericyte coverage mediated by endothelial-derived fibroblast growth factor-2 and interleukin-6 is a source of smooth muscle-like cells in pulmonary hypertension. <i>Circulation</i> , 2014 , 129, 1586-97	16.7	131
46	Chemotherapy-induced pulmonary hypertension: role of alkylating agents. <i>American Journal of Pathology</i> , 2015 , 185, 356-71	5.8	116
45	Immune dysregulation and endothelial dysfunction in pulmonary arterial hypertension: a complex interplay. <i>Circulation</i> , 2014 , 129, 1332-40	16.7	110
44	Proinflammatory Signature of the Dysfunctional Endothelium in Pulmonary Hypertension. Role of the Macrophage Migration Inhibitory Factor/CD74 Complex. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015 , 192, 983-97	10.2	108
43	Potassium Channel Subfamily K Member 3 (KCNK3) Contributes to the Development of Pulmonary Arterial Hypertension. <i>Circulation</i> , 2016 , 133, 1371-85	16.7	98
42	Therapeutic efficacy of AAV1.SERCA2a in monocrotaline-induced pulmonary arterial hypertension. <i>Circulation</i> , 2013 , 128, 512-23	16.7	85

41	The Pathobiology of Chronic Thromboembolic Pulmonary Hypertension. <i>Annals of the American Thoracic Society</i> , 2016 , 13 Suppl 3, S215-21	4.7	83
40	Mitomycin-Induced Pulmonary Veno-Occlusive Disease: Evidence From Human Disease and Animal Models. <i>Circulation</i> , 2015 , 132, 834-47	16.7	80
39	Clinical phenotypes and outcomes of heritable and sporadic pulmonary veno-occlusive disease: a population-based study. <i>Lancet Respiratory Medicine</i> , 2017 , 5, 125-134	35.1	76
38	Phenotypic Characterization of Mutation Carriers in a Large Cohort of Patients Diagnosed Clinically With Pulmonary Arterial Hypertension. <i>Circulation</i> , 2017 , 136, 2022-2033	16.7	75
37	Inhibition of MRP4 prevents and reverses pulmonary hypertension in mice. <i>Journal of Clinical Investigation</i> , 2011 , 121, 2888-97	15.9	70
36	ERS statement on chronic thromboembolic pulmonary hypertension. <i>European Respiratory Journal</i> , 2021 , 57,	13.6	70
35	Pulmonary vascular endothelium: the orchestra conductor in respiratory diseases: Highlights from basic research to therapy. <i>European Respiratory Journal</i> , 2018 , 51,	13.6	68
34	Increased oxidative stress and severe arterial remodeling induced by permanent high-flow challenge in experimental pulmonary hypertension. <i>Respiratory Research</i> , 2011 , 12, 119	7.3	64
33	Pulmonary hypertension in heart failure with preserved ejection fraction: a plea for proper phenotyping and further research. <i>European Heart Journal</i> , 2017 , 38, 2869-2873	9.5	64
32	Role for Runt-related Transcription Factor 2 in Proliferative and Calcified Vascular Lesions in Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016 , 194, 1273-1285	10.2	61
31	Bone Morphogenetic Protein Receptor Type 2 Mutation in Pulmonary Arterial Hypertension: A View on the Right Ventricle. <i>Circulation</i> , 2016 , 133, 1747-60	16.7	61
30	Occupational exposure to organic solvents: a risk factor for pulmonary veno-occlusive disease. <i>European Respiratory Journal</i> , 2015 , 46, 1721-31	13.6	55
29	BMPR2 mutation status influences bronchial vascular changes in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2016 , 48, 1668-1681	13.6	49
28	Cytotoxic cells and granulysin in pulmonary arterial hypertension and pulmonary veno-occlusive disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013 , 187, 189-96	10.2	42
27	Phenotypically Silent Bone Morphogenetic Protein Receptor 2 Mutations Predispose Rats to Inflammation-Induced Pulmonary Arterial Hypertension by Enhancing the Risk for Neointimal Transformation. <i>Circulation</i> , 2019 , 140, 1409-1425	16.7	41
26	Mechanisms of exertional dyspnoea in pulmonary veno-occlusive disease with EIF2AK4 mutations. <i>European Respiratory Journal</i> , 2014 , 44, 1069-72	13.6	33
25	Loss of KCNK3 is a hallmark of RV hypertrophy/dysfunction associated with pulmonary hypertension. <i>Cardiovascular Research</i> , 2018 , 114, 880-893	9.9	31
24	Pulmonary vascular remodeling patterns and expression of general control nonderepressible 2 (GCN2) in pulmonary veno-occlusive disease. <i>Journal of Heart and Lung Transplantation</i> , 2018 , 37, 647-655 ^{5,8}	5.8	31

23	Beyond the Lungs: Systemic Manifestations of Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020 , 201, 148-157	10.2	29
22	Resident PW1+ Progenitor Cells Participate in Vascular Remodeling During Pulmonary Arterial Hypertension. <i>Circulation Research</i> , 2016 , 118, 822-33	15.7	28
21	Right ventricular plasticity in a porcine model of chronic pressure overload. <i>Journal of Heart and Lung Transplantation</i> , 2014 , 33, 194-202	5.8	15
20	Pulmonary Arterial Histologic Lesions in Patients With COPD With Severe Pulmonary Hypertension. <i>Chest</i> , 2019 , 156, 33-44	5.3	14
19	The importance of capillary density-stroke work mismatch for right ventricular adaptation to chronic pressure overload. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2017 , 154, 2070-2079	1.5	11
18	Comparison of Human and Experimental Pulmonary Veno-Occlusive Disease. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2020 , 63, 118-131	5.7	11
17	Regulation of the Methylation and Expression Levels of the BMPR2 Gene by SIN3a as a Novel Therapeutic Mechanism in Pulmonary Arterial Hypertension. <i>Circulation</i> , 2021 , 144, 52-73	16.7	10
16	Pulmonary capillary haemangiomas: a distinct entity?. <i>European Respiratory Review</i> , 2020 , 29,	9.8	9
15	Inhibition of B cell-dependent lymphoid follicle formation prevents lymphocytic bronchiolitis after lung transplantation. <i>JCI Insight</i> , 2019 , 4,	9.9	9
14	Chronic Thromboembolic Pulmonary Hypertension and Assessment of Right Ventricular Function in the Piglet. <i>Journal of Visualized Experiments</i> , 2015 , e53133	1.6	6
13	Pulmonary vascular disease and pulmonary hypertension. <i>Diagnostic Histopathology</i> , 2019 , 25, 304-312	0.7	5
12	Natural History over 8 Years of Pulmonary Vascular Disease in a Patient Carrying Biallelic EIF2AK4 Mutations. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018 , 198, 537-541	10.2	5
11	Potential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: a global perspective. <i>Nature Reviews Cardiology</i> , 2021 ,	14.8	5
10	NADPH oxidase subunit NOXO1 is a target for emphysema treatment in COPD. <i>Nature Metabolism</i> , 2020 , 2, 532-546	14.6	4
9	Response to Letter Regarding Article, "Mitomycin-Induced Pulmonary Veno-Occlusive Disease: Evidence From Human Disease and Animal Model". <i>Circulation</i> , 2016 , 133, e592-3	16.7	4
8	Chronic thromboembolic pulmonary hypertension: the magic of pathophysiology.. <i>Annals of Cardiothoracic Surgery</i> , 2022 , 11, 106-119	4.7	3
7	Pulmonary Hypertension in Patients with Common Variable Immunodeficiency. <i>Journal of Clinical Immunology</i> , 2021 , 41, 1549-1562	5.7	2
6	Combination Therapy with STAT3 Inhibitor Enhances SERCA2a-Induced BMPR2 Expression and Inhibits Pulmonary Arterial Hypertension. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	2

5	Capillary density in right ventricular myocardium in congenital heart disease. <i>Journal of Heart and Lung Transplantation</i> , 2019 , 38, 328-331	5.8	1
4	Trichloroethylene increases pulmonary endothelial permeability: implication for pulmonary veno-occlusive disease. <i>Pulmonary Circulation</i> , 2020 , 10, 2045894020907884	2.7	1
3	Inflammation in Pulmonary Arterial Hypertension 2012 , 213-229		1
2	Smouldering fire or conflagration? An illustrated update on the concept of inflammation in pulmonary arterial hypertension.. <i>European Respiratory Review</i> , 2021 , 30,	9.8	1
1	Group 3 Pulmonary Hypertension: From Bench to Bedside.. <i>Circulation Research</i> , 2022 , 130, 1404-1422	15.7	1